Biomedical subjects

A Ulivelli

Publications and source records attributed to A Ulivelli.

At least 19 recordsLinked to original sources

PubMed1989

[Experience with anti-viral hepatitis B vaccine at an institution for handicapped children].

This study, conducted in an institute for handicapped children, is part of an overall effort to extend the anti-HBV vaccine to all high risk categories. Out of 50 patients, 24 (48%) registered negative results for all HBV markers. Twenty-three of these 24 (95.8%) were vaccinated with the Hevac-B Pasteur vaccine s.c. Of 66 employees tested, 51 resulted negative for all HBV markers (77.3%). Of these, 45 (88.2%) were vaccinated: 20 with Hevac-B vaccine s.c., 25 with HBVAX vaccine i.m. via intragluteal injection. Of the 42 who completed the study with Hevac-B, 41 showed an antibody response greater than or equal to 10 mUI (serum conversion of 97.6%). Of the 25 subjects vaccinated with HBVAX, 17 showed an immunological antibody response greater than or equal to 10 mUI (serum conversion of 68%) (p less than 0.001). This differing effectiveness is probably due to the method of injection used in administering HBVAX. It should also be noted that an intense health-education program, stressing high sanitary standards, was instrumental to the project.

Adolescent↗

PubMed1988

[Miocamycin in the therapy of bacterial infections in childhood].

Explore the source record for details and available documents.

Bacterial Infections↗

PubMed1984

[Acute nalidixic acid poisoning in an infant].

Explore the source record for details and available documents.

Humans↗

PubMed1984

Preferential increase of a T-cell subset as a cause of lymphocytosis in children with whooping cough.

T-cell subsets were examined in 17 children with whooping cough, employing OKT3, OKT4, OKT6 and OKT8 monoclonal antibodies. The degree of lymphocytosis in patients was correlated with an increase in OKT4-(helper-inducer) positive cells. These findings support the hypothesis of a disturbance in the release rather than in the homing of lymphocytes.

Antigens, Surface↗

PubMed1984

Bacillus subtilis spores as a natural pro-host oral agent. Preliminary data in children.

The commercial preparation of Bacillus subtilis spores may be considered within the classification of biological response modifiers (BRM's) and included among exogenous natural substances. Recently we decided to study the effect of a long-term B. subtilis spores oral treatment in children suffering from recurrent infectious diseases of the respiratory tract. Fifty-three children 5-9 years old have been studied. The clinical valuative parameter was the number of days of absence from school during a 4-month period. In another group of 12 diseased children, mean age 5.5 yrs we recently initiated a laboratory immunological evaluation of peripheral lymphomonocytes in relation to an oral treatment with B. subtilis spores for at least 2 months. Our results show that B. subtilis spore therapy significantly reduced the frequency of respiratory tract infections in the group of treated children. In addition, preliminary immunological laboratory evaluation demonstrated a complete return to the normal lymphomonocyte status after at least 2 months of treatment with B. subtilis spores.

Adjuvants, Immunologic↗

PubMed1978